STOCK TITAN

Jaguar Health Inc - JAGX STOCK NEWS

Welcome to our dedicated news page for Jaguar Health (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jaguar Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jaguar Health's position in the market.

Rhea-AI Summary
Jaguar Health, Inc. announced that the Take C.H.A.R.G.E Canine Cancer Registry, the first and only U.S. canine cancer registry, will join the Global Initiative for Veterinary Cancer Surveillance. The registry collects data on canine cancer diagnosis and treatment and aims to drive awareness and funding for comparative oncology research. The registry has seen a 40% increase in confirmed cancer diagnoses and has collected an additional 232,000 canine patient records.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.77%
Tags
Rhea-AI Summary
Jaguar Health, Inc. announced the addition of Stacey Tinianov, a Board Certified Patient Advocate, to its Scientific Advisory Board. Tinianov's focus as a patient advocate is on the quality of life of people undergoing cancer treatment. She will support Jaguar's mission to address cancer treatment-related diarrhea (CTD) and ensure that crofelemer reaches oncology patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.73%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.73%
Tags
conferences
-
Rhea-AI Summary
Jaguar Health reports a decrease in net revenue and an improvement in net loss for Q1 2023. The company has agreed not to issue additional equity securities until October 2023. Completed milestones include enrollment for Phase 3 OnTarget trial and planned submission of IND application for crofelemer. Jaguar also focuses on MVID as a new development goal. Net revenue for Mytesi and Canalevia-CA1 decreased and increased respectively. Prescription volume for Mytesi also decreased. Loss from operations and net loss decreased compared to the same period last year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.55%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.33%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
AI
Jaguar Health Inc

Nasdaq:JAGX

JAGX Rankings

JAGX Stock Data

24.94M
274.29M
1.78%
0.45%
8.5%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco

About JAGX

jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/